Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
How to Build $6,600 a Month in Dividend Income From Three Income Buckets
23.08.2026 16:06
Reaching $6,600 a month in dividend income sounds like a single-number problem, but the capital you actually need swings by more than a million dollars depending on which yield tier you choose and what you give up to get there.
How to Build $11,800 a Month in Dividend Income Without Selling a Single Share
23.08.2026 14:57
Collecting over $141,000 a year in dividends without selling a single share sounds like a fantasy until you realize the yield you chase determines whether your income grows, stagnates, or quietly cannibalizes itself.
Johnson & Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma
23.08.2026 14:08
Johnson & Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI®▼ (teclistamab) plus daratumumab for adults with relapsed or refractory multiple myeloma. The decision allows use of the combination as early as second line for patients whose disease has returned or is not responding to prior treatment. The approval is based on Phase 3 data that showed material improvements in patient outcomes versus existing standards of care. This adds another immunotherapy option to Johnson...
Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect
20.08.2026 13:10
Stryker (SYK) rebounds with 9% organic growth in Q2 as key segments accelerate.
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?
19.08.2026 09:22
Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.
Stryker Corporation: Hold For Quality, Wait For The Dip
18.08.2026 01:17
Stryker is a MedTech compounder with 11% organic revenue growth and expanding margins. Click here to read why SYK stock is a Hold.
Johnson & Johnson (NYSE:JNJ): A Dividend Quality Standout
17.08.2026 10:31
Johnson & Johnson passes ChartMill's Best Dividend Stocks screen with a high dividend rating, robust profitability, and solid health. A reliable income pick.
Intuitive Surgical: Priced For Precision
12.08.2026 10:57
Intuitive Surgical (ISRG) stock analysis: Hold rating with $426.65 price target (+9% upside).
What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders
11.08.2026 00:20
In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these...
ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?
10.08.2026 14:42
ISRG's premium valuation faces scrutiny as strong Q2 growth, higher margins and expanding robotic platforms support its 2026 outlook.
Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?
10.08.2026 12:42
Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]
ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers
10.08.2026 11:00
NEW YORK, August 10, 2026--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers (ASC) across the United States. The agreement encompasses an integrated portfolio of three-dimensional mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies.
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)
10.08.2026 09:16
Gileadâs 2026 outlook improves as R&D pipeline accelerates and Biktarvy & Livdelzi sales rise, lifting guidance.
This Contact Lens Stock Looks Ready to Rally
07.08.2026 06:30
Cooper Cos. could get a pop from the sale of a surgical unit. What two activists are up to in the stock.
Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?
05.08.2026 15:51
Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.
Johnson & Johnson (JNJ) Could Be 10% Overvalued Following Leadership Change
05.08.2026 06:10
Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced biopharmaceutical leader Tom Cavanaugh set to succeed her. See our latest analysis for Johnson & Johnson. Johnson & Johnson’s share price has had a strong run in 2026, with a year to date share price return of 22.95% and a 90 day share price return of 13.49%, while the 1 year total shareholder return of 53.04%...
This Surgical Robot Could Transform the Operating Room
02.08.2026 12:08
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race years earlier, or is the market already spoken for?
J&J’s biotech progress could punish its 2027 profit
01.08.2026 01:03
Johnson & Johnson (JNJ) just issued one of the weirdest profit warnings in health care. The biotech business decreased its 2026 adjusted earnings guidance to between $10.96 and $11.11 a share, from a range of $11.60 to $11.75. This year, the newly closed acquisition of Firefly Bio and the ...
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
30.07.2026 12:30
Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). If approved, it would provide a new treatment for patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Priority Review is grante